Abstract
We studied cefpirome (CPR), a new injectable cephem, for its clinical efficacy andabdominal exudate distribution.
1. The drug was administered to 11 patients with surgical infections: peritonitis in 1 patient, abdominal infection in 6, superficial suppurative diseases in 2 and secondary superficial wound infection in 2.
2. Clinical response was good in 4 patients and fair in 4, while 3 had to be excluded from the evaluation.
3. Bacteriologically, the 8 evaluable patients had monomicrobial infections, and the response was eradicated in 3 patients, decreased in 3 and persisted in 2.
4. Side effects were observed in one patient (nausea and vomiting), and abnormal laboratory findings in one patient (extension of prothrombin time).
5. The concentration of the drug in abdominal exudate was determined in two patients. The peak levels were 6.26μg/ml and 7.09μg/ml at 5 h after administration.
